Trial reportNature communications2025
Nivolumab plus ipilimumab induce hyper-progression in renal medullary carcinoma: results of a phase II trial and preclinical evidence.
Registry-linked trialAbstract readClinical Trial, Phase II
In one paragraph
Trial report in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03274258 (Phase II Trial of Nivolumab Plus Ipilimumab in Patients With Renal Medullary Carcinoma), which is not on this map. Cited by 5 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Phase II Trial of Nivolumab Plus Ipilimumab in Patients With Renal Medullary Carcinoma
Who cites it
5 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Immunotherapy in Bellini Duct Carcinoma: A Systematic Review.Oncology research · 2026Pooled it
- Advancing clinical trials for rare renal cell carcinoma subtypes: Consensus statements from the International Kidney Cancer Symposium North America 2025 think tank.Urologic oncology · 2026Article
- Renal Medullary Carcinoma: Utility of [Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026Article
- Panitumumab-Based EGFR Blockade in SMARCB1-Deficient Renal Medullary Carcinoma: Preclinical Basis and Prospective Clinical Activity.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Article
- Radiation as an immune modulator: mechanisms and implications for combination with immunotherapy.Nature reviews. Cancer · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
66 authors.
Melinda Soeung *Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0002-6902-898X
Xinmiao Yan *Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Ciro ZancaTranslational Research to Advance Therapeutics and Innovation in Oncology (TRACTION), The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Jing QianDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Menuka KarkiDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Fei DuanDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Hania KhanDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Li ZhangDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0002-7750-6427
David H PengTranslational Research to Advance Therapeutics and Innovation in Oncology (TRACTION), The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Mariah WilliamsTranslational Research to Advance Therapeutics and Innovation in Oncology (TRACTION), The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Rong HeDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Ziheng ChenDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0003-1918-106X
Luigi PerelliDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0001-7320-8193
Jianfeng ChenDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Rebecca S TidwellDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0003-3041-8582
Pankaj K ChauhanDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0002-6054-5585
Courtney N LeDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0003-4456-1478
Truong N A LamDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Nirjar BhattacharyaDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Rutvi ShahDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0002-2382-9175
I-Lin HoDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Jason P GayTranslational Research to Advance Therapeutics and Innovation in Oncology (TRACTION), The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Caroline C CarrilloTranslational Research to Advance Therapeutics and Innovation in Oncology (TRACTION), The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Ningping FengTranslational Research to Advance Therapeutics and Innovation in Oncology (TRACTION), The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Kang LeInstitute for Applied Cancer Science (IACS), Therapeutics Discovery Division, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Guang GaoTranslational Research to Advance Therapeutics and Innovation in Oncology (TRACTION), The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Teresa L PerryInstitute for Applied Cancer Science (IACS), Therapeutics Discovery Division, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Faika MseehInstitute for Applied Cancer Science (IACS), Therapeutics Discovery Division, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Yongying JiangInstitute for Applied Cancer Science (IACS), Therapeutics Discovery Division, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Quanyun A XuInstitute for Applied Cancer Science (IACS), Therapeutics Discovery Division, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Niki Marie ZachariasDepartment of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0002-9364-6016
Rahul A ShethDepartment of Interventional Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0001-9615-8985
Tharakeswara K BathalaDepartment of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Priya RaoDepartment of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0001-5672-0961
Najat C DawDepartment of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0002-6941-8005
Durga N TripathiCenter for Precision Environmental Health, Baylor college of Medicine, Houston, TX, USA.
Cheryl L WalkerCenter for Precision Environmental Health, Baylor college of Medicine, Houston, TX, USA.ORCID http://orcid.org/0000-0002-4233-3247
Mohammad M MohammadInstitute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Jianhua ZhangDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0001-5412-9860
Guangchun HanDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0001-9277-2507
Yanshuo ChuDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Ruiping WangDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Minghao DangDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0001-7287-2877
Enyu DaiDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Fuduan PengDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Yunhe LiuDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0002-2120-952X
Akshaya JadhavDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0002-1851-1306
Wenhua LangDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Claudio A ArrechederaDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0009-0001-5358-480X
Leticia Campos ClementeDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0002-7917-8543
Edwin R ParraDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0001-9068-1636
Hsinyi LuDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Cara L HaymakerDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0002-1317-9287
Ignacio I WistubaDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Andrew FutrealDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0001-8663-2671
Andrea VialeDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Michael J SothInstitute for Applied Cancer Science (IACS), Therapeutics Discovery Division, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Philip JonesInstitute for Applied Cancer Science (IACS), Therapeutics Discovery Division, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID http://orcid.org/0000-0001-6149-8293
Joseph R MarszalekInstitute for Applied Cancer Science (IACS), Therapeutics Discovery Division, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID http://orcid.org/0000-0003-2320-3209
Timothy HeffernanTranslational Research to Advance Therapeutics and Innovation in Oncology (TRACTION), The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0002-3166-8922
Giulio F DraettaTranslational Research to Advance Therapeutics and Innovation in Oncology (TRACTION), The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0001-5225-9610
Nizar M TannirDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0001-5559-8060
Jianjun GaoDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. jgao1@mdanderson.org.ORCID http://orcid.org/0000-0001-6138-4472
Linghua WangDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. lwang22@mdanderson.org.ORCID http://orcid.org/0000-0001-9380-0266
Giannicola GenoveseDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. ggenovese@mdanderson.org.ORCID http://orcid.org/0000-0003-1392-9954
Pavlos MsaouelDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. pmsaouel@mdanderson.org.ORCID http://orcid.org/0000-0001-6505-8308
Funding
Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8MInvestigation of the role of epithelial-mesenchymal plasticity in renal cell carcinomaR01CA258226 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI GENOVESE, GIANNICOLA · 2021 to 2025
$2.9MEffective combination therapy for MTAP-deficient bladder carcinoma by targeting metabolic vulnerability and modulating tumor immune microenvironmentR01CA254988 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI GAO, JIANJUN · 2021 to 2025
$2.6MElucidating T Cell Ferroptosis in Renal Medullary Carcinoma: 3D Genome Architecture Rewiring and Therapeutic AlleviationR01CA285454 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Wenbo Li, Pavlos Msaouel · 2024 to 2026
$2.0MMechanisms of Hyperprogression to Immunotherapy in SMARCB1-Deficient Renal MalignanciesR37CA288448 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Pavlos Msaouel · 2024 to 2026
$2.0MInvestigation of the cell of origin and evolutionary trajectories of human glioblastomaR03NS145168 · NINDS · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Luigi Perelli · 2025 to 2026
$164kNCI NIH HHS P30 CA016672NCI NIH HHS R01 CA254988NCI NIH HHS R01 CA258226NCI NIH HHS R01 CA285454NCI NIH HHS R37 CA288448NINDS NIH HHS R03 NS145168U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) R37CA288448
Abstract
Therapeutic options for patients with renal medullary carcinoma (RMC) are limited. Here we report the results of a phase II clinical trial (NCT03274258) of anti-PD1 nivolumab plus anti-CTLA4 ipilimumab in patients with RMC, with objective response rate as primary outcome. Enrollment was halted for futility at a prespecified interim analysis as all 10 treated patients experienced rapid disease progression. 5/10 met radiological criteria for hyperprogression and median progression-free survival (secondary outcome) was 1.38 months (95% confidence interval: 1.28, 1.60). In a post-hoc single-cell RNA sequencing analysis, data from patients with RMC before and after nivolumab plus ipilimumab treatment indicated that immune checkpoint therapy (ICT) triggered an interferon-γ response that induced a "myeloid mimicry" program in tumor cells, regulated by the CEBPB / p300 axis and linked to proliferation and hyperprogression. In preclinical experiments using an immunocompetent somatic mosaic genetically engineered mouse model of RMC, combination ICT accelerated tumor growth while activating myeloid-affiliated transcriptional circuits. Selective pharmacologic inhibition of p300 suppressed this program and restored sensitivity to ICT. These findings reveal an adaptive mechanism of resistance to ICT in RMC and support targeting master myeloid regulators to enable therapeutic benefit.
Indexed as
Antineoplastic Combined Chemotherapy ProtocolsCarcinoma, MedullaryCarcinoma, Renal CellIpilimumabKidney NeoplasmsNivolumabAdultAgedAnimalsDisease ProgressionFemaleHumansImmune Checkpoint InhibitorsMaleMiceMiddle AgedImmune Checkpoint InhibitorsIpilimumabNivolumab
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
NCT03274258ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.